Amicus Therapeutics (NASDAQ: FOLD) and Sophiris Bio (NASDAQ:SPHS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.


This table compares Amicus Therapeutics and Sophiris Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amicus Therapeutics -1,092.37% -63.54% -23.46%
Sophiris Bio N/A -85.20% -38.89%

Insider & Institutional Ownership

5.8% of Sophiris Bio shares are held by institutional investors. 3.4% of Amicus Therapeutics shares are held by company insiders. Comparatively, 3.9% of Sophiris Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Amicus Therapeutics and Sophiris Bio’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Amicus Therapeutics $4.96 million 439.48 -$200.04 million ($1.83) -7.16
Sophiris Bio N/A N/A -$11.16 million ($0.18) -11.44

Sophiris Bio has higher revenue, but lower earnings than Amicus Therapeutics. Sophiris Bio is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Amicus Therapeutics and Sophiris Bio, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amicus Therapeutics 0 1 6 0 2.86
Sophiris Bio 0 0 4 0 3.00

Amicus Therapeutics currently has a consensus price target of $18.07, suggesting a potential upside of 37.84%. Sophiris Bio has a consensus price target of $6.25, suggesting a potential upside of 203.40%. Given Sophiris Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Sophiris Bio is more favorable than Amicus Therapeutics.

Risk and Volatility

Amicus Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Sophiris Bio has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.


Sophiris Bio beats Amicus Therapeutics on 7 of the 12 factors compared between the two stocks.

About Amicus Therapeutics

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

About Sophiris Bio

Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with's FREE daily email newsletter.